Click here to get full coverage on PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment - Stocktwits

PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment  Stocktwits

PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment - Stocktwits

Click here to get full coverage on Blue Owl Capital Holdings LP Reduces Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat

Blue Owl Capital Holdings LP Reduces Position in Palvella Therapeutics, Inc. $PVLA  MarketBeat

Blue Owl Capital Holdings LP Reduces Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat

Click here to get full coverage on Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple - Yahoo Finance

Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple  Yahoo Finance

Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple - Yahoo Finance

Click here to get full coverage on Wednesday 3/4 Insider Buying Report: XRAY, PVLA - Nasdaq

Wednesday 3/4 Insider Buying Report: XRAY, PVLA  Nasdaq

Wednesday 3/4 Insider Buying Report: XRAY, PVLA - Nasdaq

Click here to get full coverage on Insider Purchase: Director at $PVLA Buys 4,000 Shares - Quiver Quantitative

Insider Purchase: Director at $PVLA Buys 4,000 Shares  Quiver Quantitative

Insider Purchase: Director at $PVLA Buys 4,000 Shares - Quiver Quantitative

Click here to get full coverage on PVLA Stock Surges 86% With A 6-day Winning Spree On Phase 3 Win - Trefis

PVLA Stock Surges 86% With A 6-day Winning Spree On Phase 3 Win  Trefis

PVLA Stock Surges 86% With A 6-day Winning Spree On Phase 3 Win - Trefis

Click here to get full coverage on Palvella therapeutics (PVLA) director buys $500k in stock - Investing.com South Africa

Palvella therapeutics (PVLA) director buys $500k in stock  Investing.com South Africa

Palvella therapeutics (PVLA) director buys $500k in stock - Investing.com South Africa

Click here to get full coverage on Is Palvella Therapeutics (PVLA) Still Attractive After A 7x One-Year Surge In Price? - simplywall.st

Is Palvella Therapeutics (PVLA) Still Attractive After A 7x One-Year Surge In Price?  simplywall.st

Is Palvella Therapeutics (PVLA) Still Attractive After A 7x One-Year Surge In Price? - simplywall.st

Click here to get full coverage on Palvella stock surges on late-stage trial win (PVLA:NASDAQ) - Seeking Alpha

Palvella stock surges on late-stage trial win (PVLA:NASDAQ)  Seeking Alpha

Palvella stock surges on late-stage trial win (PVLA:NASDAQ) - Seeking Alpha

Click here to get full coverage on Assessing Palvella Therapeutics (PVLA) Valuation After Its Recent Share Price Surge - Sahm

Assessing Palvella Therapeutics (PVLA) Valuation After Its Recent Share Price Surge  Sahm

Assessing Palvella Therapeutics (PVLA) Valuation After Its Recent Share Price Surge - Sahm

Click here to get full coverage on Royce & Associates LP Decreases Stock Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat

Royce & Associates LP Decreases Stock Holdings in Palvella Therapeutics, Inc. $PVLA  MarketBeat

Royce & Associates LP Decreases Stock Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat

Click here to get full coverage on Palvella (PVLA) Stock Pre-Market (+13%): Phase 3 Topline Data Anticipation - Trefis

Palvella (PVLA) Stock Pre-Market (+13%): Phase 3 Topline Data Anticipation  Trefis

Palvella (PVLA) Stock Pre-Market (+13%): Phase 3 Topline Data Anticipation - Trefis

Click here to get full coverage on Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - Sahm

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares  Sahm

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - Sahm

Click here to get full coverage on Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Update - MarketBeat

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Update  MarketBeat

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Update - MarketBeat

Click here to get full coverage on Insider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Acquires 4,000 Shares of Stock - MarketBeat

Insider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Acquires 4,000 Shares of Stock  MarketBeat

Insider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Acquires 4,000 Shares of Stock - MarketBeat

Click here to get full coverage on Palvella Therapeutics (NASDAQ:PVLA) Director Elaine Heron Purchases 2,400 Shares - MarketBeat

Palvella Therapeutics (NASDAQ:PVLA) Director Elaine Heron Purchases 2,400 Shares  MarketBeat

Palvella Therapeutics (NASDAQ:PVLA) Director Elaine Heron Purchases 2,400 Shares - MarketBeat

Click here to get full coverage on What is Lifesci Capital's Estimate for PVLA FY2026 Earnings? - MarketBeat

What is Lifesci Capital's Estimate for PVLA FY2026 Earnings?  MarketBeat

What is Lifesci Capital's Estimate for PVLA FY2026 Earnings? - MarketBeat

Click here to get full coverage on HC Wainwright Has Optimistic Outlook of PVLA FY2027 Earnings - MarketBeat

HC Wainwright Has Optimistic Outlook of PVLA FY2027 Earnings  MarketBeat

HC Wainwright Has Optimistic Outlook of PVLA FY2027 Earnings - MarketBeat

Click here to get full coverage on Aberdeen Group plc Makes New Investment in Palvella Therapeutics, Inc. $PVLA - MarketBeat

Aberdeen Group plc Makes New Investment in Palvella Therapeutics, Inc. $PVLA  MarketBeat

Aberdeen Group plc Makes New Investment in Palvella Therapeutics, Inc. $PVLA - MarketBeat

Click here to get full coverage on Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals - Yahoo Finance

Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals  Yahoo Finance

Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals - Yahoo Finance

Click here to get full coverage on Palvella Therapeutics, Inc. (PVLA) Stock Analysis: A Potential 74% Upside in the Biotech Sector - DirectorsTalk Interviews

Palvella Therapeutics, Inc. (PVLA) Stock Analysis: A Potential 74% Upside in the Biotech Sector  DirectorsTalk Interviews

Palvella Therapeutics, Inc. (PVLA) Stock Analysis: A Potential 74% Upside in the Biotech Sector - DirectorsTalk Interviews

Click here to get full coverage on Palvella Therapeutics (NASDAQ:PVLA) Trading Up 5.9% - Here's Why - MarketBeat

Palvella Therapeutics (NASDAQ:PVLA) Trading Up 5.9% - Here's Why  MarketBeat

Palvella Therapeutics (NASDAQ:PVLA) Trading Up 5.9% - Here's Why - MarketBeat

Click here to get full coverage on Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $250.00 at Mizuho - MarketBeat

Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $250.00 at Mizuho  MarketBeat

Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $250.00 at Mizuho - MarketBeat

Click here to get full coverage on BTIG Research Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $215.00 - MarketBeat

BTIG Research Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $215.00  MarketBeat

BTIG Research Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $215.00 - MarketBeat

Click here to get full coverage on Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High - Time to Buy? - MarketBeat

Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High - Time to Buy?  MarketBeat

Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High - Time to Buy? - MarketBeat

Click here to get full coverage on Strategic Acquisition Expands PVLA’s Market Reach in Europe - StocksToTrade

Strategic Acquisition Expands PVLA’s Market Reach in Europe  StocksToTrade

Strategic Acquisition Expands PVLA’s Market Reach in Europe - StocksToTrade

Click here to get full coverage on Palvella Therapeutics Announces Pricing of Upsized Public Offering - ChartMill

Palvella Therapeutics Announces Pricing of Upsized Public Offering  ChartMill

Palvella Therapeutics Announces Pricing of Upsized Public Offering - ChartMill

Click here to get full coverage on Chardan Capital Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $210.00 - MarketBeat

Chardan Capital Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $210.00  MarketBeat

Chardan Capital Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $210.00 - MarketBeat

Click here to get full coverage on Palvella Therapeutics (PVLA) Price Target Increased by 15.61% to 133.70 - Nasdaq

Palvella Therapeutics (PVLA) Price Target Increased by 15.61% to 133.70  Nasdaq

Palvella Therapeutics (PVLA) Price Target Increased by 15.61% to 133.70 - Nasdaq

Click here to get full coverage on Palvella Therapeutics (NASDAQ:PVLA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Palvella Therapeutics (NASDAQ:PVLA) Is In A Good Position To Deliver On Growth Plans  Yahoo Finance

Palvella Therapeutics (NASDAQ:PVLA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Click here to get full coverage on (PVLA) Movement as an Input in Quant Signal Sets - Stock Traders Daily

(PVLA) Movement as an Input in Quant Signal Sets  Stock Traders Daily

(PVLA) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Click here to get full coverage on Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Rating of "Buy" by Analysts  MarketBeat

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Click here to get full coverage on $PVLA stock is down 14% today. Here's what we see in our data. - Quiver Quantitative

$PVLA stock is down 14% today. Here's what we see in our data.  Quiver Quantitative

$PVLA stock is down 14% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Support Test: Can PVLA stock double in the next year - Weekly Investment Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn

Support Test: Can PVLA stock double in the next year - Weekly Investment Report & Free Fast Gain Swing Trade Alerts  baoquankhu1.vn

Support Test: Can PVLA stock double in the next year - Weekly Investment Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn

Click here to get full coverage on Palvella Therapeutics Announces Pricing of Upsized Public Offering - Sahm

Palvella Therapeutics Announces Pricing of Upsized Public Offering  Sahm

Palvella Therapeutics Announces Pricing of Upsized Public Offering - Sahm

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail

Click here to get full coverage on Palvella Therapeutics Announces Pricing Of Upsized Public Offering - TradingView

Palvella Therapeutics Announces Pricing Of Upsized Public Offering  TradingView

Palvella Therapeutics Announces Pricing Of Upsized Public Offering - TradingView

Click here to get full coverage on Global Pharma Merger: PVLA’s Game-Changer - timothysykes.com

Global Pharma Merger: PVLA’s Game-Changer  timothysykes.com

Global Pharma Merger: PVLA’s Game-Changer - timothysykes.com

Click here to get full coverage on FY2030 Earnings Estimate for PVLA Issued By HC Wainwright - MarketBeat

FY2030 Earnings Estimate for PVLA Issued By HC Wainwright  MarketBeat

FY2030 Earnings Estimate for PVLA Issued By HC Wainwright - MarketBeat

Click here to get full coverage on High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin - Yahoo Finance

High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin  Yahoo Finance

High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin - Yahoo Finance

Click here to get full coverage on $PVLA stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

$PVLA stock is up 11% today. Here's what we see in our data.  Quiver Quantitative

$PVLA stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on BTIG Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $215 - 富途牛牛

BTIG Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $215  富途牛牛

BTIG Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $215 - 富途牛牛

Click here to get full coverage on A new gel that could become the first treatment for rare skin diseases - Stock Titan

A new gel that could become the first treatment for rare skin diseases  Stock Titan

A new gel that could become the first treatment for rare skin diseases - Stock Titan

Click here to get full coverage on Palvella Therapeutics (PVLA) Price Target Increased by 39.58% to 115.65 - Nasdaq

Palvella Therapeutics (PVLA) Price Target Increased by 39.58% to 115.65  Nasdaq

Palvella Therapeutics (PVLA) Price Target Increased by 39.58% to 115.65 - Nasdaq

Click here to get full coverage on Liquidity Mapping Around (PVLA) Price Events - Stock Traders Daily

Liquidity Mapping Around (PVLA) Price Events  Stock Traders Daily

Liquidity Mapping Around (PVLA) Price Events - Stock Traders Daily

Click here to get full coverage on A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $209 to $267 - 富途牛牛

A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $209 to $267  富途牛牛

A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $209 to $267 - 富途牛牛

Click here to get full coverage on Craig-Hallum Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $205 - 富途牛牛

Craig-Hallum Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $205  富途牛牛

Craig-Hallum Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $205 - 富途牛牛

Click here to get full coverage on Palvella Therapeutics Directors Quietly Make Bold Insider Moves - TipRanks

Palvella Therapeutics Directors Quietly Make Bold Insider Moves  TipRanks

Palvella Therapeutics Directors Quietly Make Bold Insider Moves - TipRanks

Click here to get full coverage on New Analyst Forecast: $PVLA Given $192 Price Target - Quiver Quantitative

New Analyst Forecast: $PVLA Given $192 Price Target  Quiver Quantitative

New Analyst Forecast: $PVLA Given $192 Price Target - Quiver Quantitative

Click here to get full coverage on Palvella Reports Positive Phase 3 Data for QTORIN - TipRanks

Palvella Reports Positive Phase 3 Data for QTORIN  TipRanks

Palvella Reports Positive Phase 3 Data for QTORIN - TipRanks

Click here to get full coverage on Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst (NASDAQ:PVLA) - Seeking Alpha

Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst (NASDAQ:PVLA)  Seeking Alpha

Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst (NASDAQ:PVLA) - Seeking Alpha

Click here to get full coverage on Robust Phase 3 SELVA Results for QTORIN Rapamycin Drive Confident Buy Rating on PVLA - TipRanks

Robust Phase 3 SELVA Results for QTORIN Rapamycin Drive Confident Buy Rating on PVLA  TipRanks

Robust Phase 3 SELVA Results for QTORIN Rapamycin Drive Confident Buy Rating on PVLA - TipRanks

Click here to get full coverage on Palvella (Nasdaq: PVLA) secures FDA Fast Track Designation for QTORIN angiokeratomas - Stock Titan

Palvella (Nasdaq: PVLA) secures FDA Fast Track Designation for QTORIN angiokeratomas  Stock Titan

Palvella (Nasdaq: PVLA) secures FDA Fast Track Designation for QTORIN angiokeratomas - Stock Titan

Click here to get full coverage on Adagene, Palvella up after FDA Fast Track tags (ADAG:NASDAQ) - Seeking Alpha

Adagene, Palvella up after FDA Fast Track tags (ADAG:NASDAQ)  Seeking Alpha

Adagene, Palvella up after FDA Fast Track tags (ADAG:NASDAQ) - Seeking Alpha

Click here to get full coverage on The Short-Sellers May Be Right About This Red-Hot Pharma Stock - Yahoo Finance

The Short-Sellers May Be Right About This Red-Hot Pharma Stock  Yahoo Finance

The Short-Sellers May Be Right About This Red-Hot Pharma Stock - Yahoo Finance

Click here to get full coverage on Trading the Move, Not the Narrative: (PVLA) Edition - Stock Traders Daily

Trading the Move, Not the Narrative: (PVLA) Edition  Stock Traders Daily

Trading the Move, Not the Narrative: (PVLA) Edition - Stock Traders Daily

Click here to get full coverage on Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright - Yahoo Finance

Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright  Yahoo Finance

Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright - Yahoo Finance

Click here to get full coverage on Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $205 - 富途牛牛

Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $205  富途牛牛

Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $205 - 富途牛牛

Click here to get full coverage on Is Palvella Therapeutics (NASDAQ:PVLA) Weighed On By Its Debt Load? - simplywall.st

Is Palvella Therapeutics (NASDAQ:PVLA) Weighed On By Its Debt Load?  simplywall.st

Is Palvella Therapeutics (NASDAQ:PVLA) Weighed On By Its Debt Load? - simplywall.st

Click here to get full coverage on Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares - Bitget

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares  Bitget

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares - Bitget

Click here to get full coverage on Palvella Therapeutics, Inc. (PVLA) Stock Analysis: Unpacking a Promising 74% Upside Potential - DirectorsTalk Interviews

Palvella Therapeutics, Inc. (PVLA) Stock Analysis: Unpacking a Promising 74% Upside Potential  DirectorsTalk Interviews

Palvella Therapeutics, Inc. (PVLA) Stock Analysis: Unpacking a Promising 74% Upside Potential - DirectorsTalk Interviews

Click here to get full coverage on Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM (NASDAQ:PVLA) - Seeking Alpha

Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM (NASDAQ:PVLA)  Seeking Alpha

Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM (NASDAQ:PVLA) - Seeking Alpha

Click here to get full coverage on Palvella Therapeutics Announces Underwritten Common Stock Offering - TipRanks

Palvella Therapeutics Announces Underwritten Common Stock Offering  TipRanks

Palvella Therapeutics Announces Underwritten Common Stock Offering - TipRanks

Click here to get full coverage on Truist raises Palvella Therapeutics stock price target on phase 3 data - Investing.com

Truist raises Palvella Therapeutics stock price target on phase 3 data  Investing.com

Truist raises Palvella Therapeutics stock price target on phase 3 data - Investing.com

Click here to get full coverage on Palvella Reports Positive Phase 3 Data for QTORIN Gel - TipRanks

Palvella Reports Positive Phase 3 Data for QTORIN Gel  TipRanks

Palvella Reports Positive Phase 3 Data for QTORIN Gel - TipRanks

Click here to get full coverage on Palvella Therapeutics Reports Positive Phase 2 Study Results - TipRanks

Palvella Therapeutics Reports Positive Phase 2 Study Results  TipRanks

Palvella Therapeutics Reports Positive Phase 2 Study Results - TipRanks

Click here to get full coverage on Palvella Therapeutics, Inc Advances Late-Stage Pipeline - TradingView

Palvella Therapeutics, Inc Advances Late-Stage Pipeline  TradingView

PVLA

Price Chart

Key Statistics

Technicals

About PVLA

Latest News

PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment - Stocktwits

Blue Owl Capital Holdings LP Reduces Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat

Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers